ImageneBio Advances IMG-007 Trial with Protocol Expansion and Strong Cash Position
Event summary
- ImageneBio reported $135.3 million in cash as of December 31, 2025, up from $12.1 million a year earlier, following a $75 million private placement.
- The Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis is ongoing with topline data expected in 2027.
- Protocol amendment submitted to expand dosing regimens and evaluate patient-friendly intervals.
- Dr. Ben Porter-Brown joined as Chief Medical Officer, bringing extensive inflammation and dermatology experience.
The big picture
ImageneBio's strategic shift towards a focused inflammation and autoimmune pipeline, backed by a robust cash position, positions it to compete in the growing OX40/OX40L antagonist space. The company's emphasis on safety and patient-friendly dosing could differentiate IMG-007 in a crowded market.
What we're watching
- Clinical Trial Execution
- Whether the protocol amendment will accelerate or complicate the ADAPTIVE trial timeline.
- Competitive Differentiation
- How IMG-007's non-T cell depleting profile will position it against competitors like rocatinlimab.
- Financial Runway
- The pace at which ImageneBio will need to secure additional funding to support Phase 3 trials.
Related topics